Transaction · 0001810417-26-000019

Sullivan Christopher Ryan

Sullivan Christopher Ryan, CFO, reported a transaction classified as exercise at Avalo Therapeutics, Inc. involving 37945.000000 shares for an estimated $0.00. Reported holdings after the transaction were 130149.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MCFO
AVTXAvalo Therapeutics, Inc.
Filing timeAug 19
Trade dateAug 17, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$20.75
Pre-filing
1mo ago -6.7%1w ago -4.7%1d ago -5.6%
Returns since
7d -1.0%30d -8.7%90d -8.7%180d -8.7%1y -8.7%

AVTX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
AVTX since 2026-08-19Filed 15 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001810417-26-000019
Stock Option (Right to Buy)
Transaction date
Aug 17, 2026
Filed Aug 19, 2026, 08:10 PM · 2d delay
Shares
37.9k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
130k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Derivative Transaction Direct Ownership Large Holdings Reduction 10b5-1 Detected
-16score
Filing-only score

-16

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.

  2. F2

    The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the s…

  3. F3

    The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the s…

  4. F4

    The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the…

  5. F5

    The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

Original filing · 0001810417-26-000019
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

AVTX